Resverlogix Corp. (TSE:RVX – Get Free Report) shares hit a new 52-week low on Monday . The stock traded as low as C$0.04 and last traded at C$0.04, with a volume of 1525 shares changing hands. The stock had previously closed at C$0.05.
Resverlogix Stock Performance
The business’s fifty day moving average is C$0.05 and its two-hundred day moving average is C$0.06. The company has a current ratio of 0.13, a quick ratio of 0.04 and a debt-to-equity ratio of -10.95. The company has a market capitalization of C$7.92 million, a PE ratio of -1.98 and a beta of 0.71.
About Resverlogix
Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.
See Also
- Five stocks we like better than Resverlogix
- The Role Economic Reports Play in a Successful Investment Strategy
- Super Micro Stock: $7.2M Call Options Signal Big Upside Potential
- When to Sell a Stock for Profit or Loss
- Top 3 Buy-and-Hold Stocks for 2025: Long-Term Winners to Watch
- How to Profit From Value Investing
- D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst?
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
